The clinical value of CA-15-3 and CEA in breast cancer

Objective To evaluate the clinical value of CA-15-3 and CEA in breast cancer. Methods With ECLusys1010 electrochemical luminescence instrument, the level of CA-15-3,CEA in 62 breast cancer patients,22 benign breast disease patients and 20 normal people (as control) were detected. Results The expression of CA-15-3 and CEA in breast cancer at Ⅰ,Ⅱ,Ⅲ stage, benign breast disease group and normal control group had no significant difference(P0.05), while the numerical value had increasing trend, and their expression in breast cancer at Ⅳ stage was significantly higher than that of the other groups(P0.01;P0.05), and the expression in group of having organ metastasis was significantly higher than that of having simply lymphoma metastasis group and non-lymphoma metastasis group(P0.01); the level of CA-15-3 and CEA had no significant difference in patients with different tissue origin breast cancer(P0.05). Conclusion CA-15-3 and CEA are not ideal tumor marker in diagnosing early breast cancer, but their expression are correlated significantly with tumor staging, organ metastasis and lymphaden metastasis; they have important value in forecasting tumor metastasis, recurrence and monitoring curative effect and judging prognosis, their expression had no tissue and cell specificity.